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Photodynamic therapy (PDT) is believed to promote 
hypoxic conditions to tumor cells leading to overexpres-
sion of angiogenic markers such as vascular endothelial 
growth factor (VEGF). In this study, PDT was combined 
with lipid–calcium–phosphate nanoparticles (LCP NPs) 
to deliver VEGF-A small interfering RNA (siVEGF-A) 
to human head and neck squamous cell carcinoma 
(HNSCC) xenograft models. VEGF-A were significantly 
decreased for groups treated with siVEGF-A in human 
oral squamous cancer cell (HOSCC), SCC4 and SAS 
models. Cleaved caspase-3 and in situ TdT-mediated 
dUTP nick-end labeling assay showed more apoptotic 
cells and reduced Ki-67 expression for treated groups 
compared to phosphate buffered saline (PBS) group. 
Indeed, the combined therapy showed significant tumor 
volume decrease to ~70 and ~120% in SCC4 and SAS 
models as compared with untreated PBS group, respec-
tively. In vivo toxicity study suggests no toxicity of such 
LCP NP delivered siVEGF-A. In summary, results suggest 
that PDT combined with targeted VEGF-A gene therapy 
could be a potential therapeutic modality to achieve 
enhanced therapeutic outcome for HNSCC.
Received 28 February 2015; accepted 28 August 2015; advance online  
publication 3 November 2015. doi:10.1038/mt.2015.169
INTRODUCTION
Head and neck cancers develop in the hypopharynx, larynx, sino-
nasal, and oral cavity,1 and 95% head and neck cancer is squa-
mous cell carcinoma.2 It is affected by exogeneous risk factors 
such as tobacco, alcohol consumption, and infection of human 
papilloma virus.2 Head and neck cancers are usually treated by 
surgery, radiotherapy, and chemotherapy. Photodynamic therapy 
(PDT) is considered as an alternative treatment for precancerous 
and cancerous oral lesions due to its noninvasive nature and mini-
mal cumulative side effects even after repetitive treatments which 
results in negligible scar formation.3,4
PDT utilizes a photosensitizing drug that selectively destroys 
tumor cells when activated by light.5 The photodynamic reaction 
produces reactive oxygen species that can kill tumor cells. PDT 
can induce the expression of the hypoxia-inducible factor (HIF), 
HIF-1α, which is the key mediator of oxygen homeostasis under 
hypoxic conditions and its target genes in vitro and in vivo.6 The 
PDT-induced oxygen insult activates proangiogenic molecules 
which affect the efficacy of the treatment.6–8 One of HIF target 
genes is the vascular endothelial growth factor-A (VEGF-A or 
VEGF) which is overexpressed on malignant tumors and is the 
key regulator of angiogenesis.9,10 It was found that VEGF-A are 
expressed on human head and neck squamous cell carcinomas 
(HNSCC)11 and oral squamous cell carcinomas.12 Studies have 
shown that VEGF are overexpressed after PDT. Therefore, there is 
combined treatment with antiangiogenic molecules such as anti-
VEGF monoclonal antibodies (e.g., bevacizumab)7,13 to block 
angiogenesis. However, the use of anti-VEGF inhibitors can 
cause additional adverse effects such as hypertension and pro-
teinuria and lead to decreased therapeutic response in patients.14
Small interfering RNA (siRNA) which is specific to VEGF-A 
and delivered properly to tumor cells may overcome these dis-
tinct adverse effects. It was demonstrated that at 30 and 50 nmol/l 
of transfected VEGF siRNA to human HNSCC cells can decrease 
cell proliferation.11 In order to deliver the siRNA to the tumor 
cells efficiently, lipid-based nanoparticles can be used such as the 
lipid–calcium–phosphate nanoparticles (LCP NPs). The target-
ing ligand, anisamide (AA), was modified on the outer-leaflet of 
LCP NPs to specifically target the sigma receptors15 which are 
overexpressed on HNSCC cells.16 The use of targeted LCP NPs 
loaded with VEGF siRNA and gemcitabine monophosphate 
revealed an improved therapeutic response than VEGF siRNA 
or gemcitabine monophosphate therapy alone that resulted to 
decrease tumor microvessel density and induced cell apoptosis in 
non–small-cell lung cancer xenograft models.17
The objective of this study was to evaluate the in vivo thera-
peutic effect of combining photosan-mediated PDT with VEGF-A 
siRNA gene therapy loaded in targeted LCP NPs to inhibit tumor 
growth in subcutaneous human HNSCC xenograft models of 
SCC4 and SAS.
RESULTS
Characterization of LCP NPs
LCP NP is an asymmetric lipid bilayer nanoparticle that is com-
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by an anionic lipid dioleoylphosphatidic acid, and the outer layer 
was coated with cationic lipid 1,2-dioleoyl-3-trimethylammo-
nium-propane chloride salt. The outer leaflet is grafted with poly-
ethylene glycol (PEG) chains modified with AA, a sigma receptor 
targeting ligand (Figure 1a).
The transmission electron microscope (TEM) photomicro-
graphs showed a particle size that ranges from 25 to 30 nm which 
is smaller than the hydrodynamic diameter measured by dynamic 
light scattering which ranges from 35 to 40 nm since TEM is con-
ducted in a dehydrated condition (Figure 1b–d). The measured 
zeta potential for the LCP NPs was 46.2 ± 0.6 mV.
In vitro sigma receptor and VEGF-A expression on 
human HNSCC cells
We have previously shown that sigma receptor is expressed on 
human SCC4 and SAS HNSCC cell lines.16 In this study, sigma 
receptor and VEGF-A protein expression was observed 24 
hours post-PDT. The cells were treated with 0.5 µg/ml photo-
san (PS) at 10 J/cm2 for 159 seconds and were incubated with 
growth medium for 24 hours before protein extraction. As 
shown in Figure 2a, VEGF-A was upregulated 24 hours post-
PDT as compared with untreated cells and the amount of sigma 
receptor was not downregulated by the treatment thus the LCP 
NPs can target sigma receptor–expressing HNSCC cells even 
after PDT.
Both SCC4 and SAS cells were transfected with the 25 nmol/l 
self-designed VEGF-A siRNA (siRNA), and VEGF-A protein 
expression was observed after 48 hours by western blotting. There 
was a VEGF-A–silencing effect observed for cells treated with 
VEGF-A siRNA (siVEGF-A; Figure 2b) as compared to groups 
treated with phosphate buffered saline (PBS) or nontargeting 
 siScrambled. This shows that the self-designed siVEGF-A sequence 
can silence the VEGF-A protein expression at cellular level.
In vivo tumor growth inhibition of combined PDT and 
siVEGF-A therapy
Human HNSCC SCC4 and SAS xenograft models with 315–
385 mm3 tumor volume were randomly separated into five 
treatment groups (Supplementary Table S1): (i) PBS; (ii) 
PDT+siScrambled; (iii) PS+siVEGF-A; (iv) PBS+Light+siVEGF-A; 
and (v) PDT+siVEGF-A. For a full treatment within 11 days, the 
mice received the two cycles of therapy with 1-day interval from 
the first cycle. The mice were given tail vein injections on days 0 
and 5 with either PBS or 2 mg/kg PS and were irradiated with 640-
nm light for the PDT+siScrambled, PBS+light+siVEGF-A, and 
PDT+siVEGF-A groups. Then, they received daily tail vein injec-
tion of LCP NPs loaded with either siScrambled or siVEGF-A on 
days 1, 2, 3 and 6, 7, 8. The mice were sacrificed on the 11th day.
For the SCC4 xenograft models, as shown in Figure 3a, the PBS 
group grows the tumor up to 47% from the start of the treatment. 
Figure 1 Characterization of LCP NPs. (a) Illustration of asymmetric bilayer. (b) TEM photomicrograph of LCP NPs loaded with siVEGF-A, Bar = 
100 nm. (c) Size distribution of LCP NPs loaded with siVEGF-A. (d) Average LCP NPs particle size and zeta potential of LCP NPs loaded with siVEGF-A 
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PDT+siScrambled group decreased the tumor volume 3 days after 
the PDT treatment and slowed down the growth of the tumor 
with a −3.3% inhibition showing a significant difference (P < 0.01) 
when compared with PBS and PDT+ siVEGF-A groups. On the 
other hand, PS+siVEGF-A and PBS+Light+siVEGF-A groups 
showed −9.9 and −5.4% tumor inhibitions which is showed signif-
icant differences when compared with PBS and PDT+siVEGF-A. 
These two groups showed the tumor inhibition effect of siVEGF-A 
in the absence of full PDT treatment. PDT+siVEGF-A group 
showed the slowest growth rate significantly (P < 0.01) among 
the five groups with −30.7% tumor inhibition and about ~70% 
difference from the PBS group. The combined therapy of PDT 
and siVEGF-A-loaded LCP NPs showed significant difference 
(P < 0.01) between PDT+siScrambled group showing the enhance-
ment of tumor inhibition by silencing in vivo VEGF-A after PDT. 
The combined therapy showed significant tumor volume decrease 
to ~70% in SCC4 model as compared with untreated PBS group.
Similar trend was observed for the SAS xenograft models as 
shown in Figure 3b. The PBS group showed higher growth rate of 
95.2%, which also shows that SAS tumors grow faster than SCC4. 
The effect of the PDT was observed with the PDT+siScrambled 
group which has a tumor growth rate of 34.1%, significantly 
slower (P < 0.01) than the PBS group. On the other hand, the 
effect of the siVEGF-A to the SAS xenografts was observed 
with the two groups that were treated with incomplete PDT and 
siVEGF-A–loaded LCP NPs. The tumor growth rate significantly 
decreased (P < 0.01) to 6.3% for PS +siVEGF-A group and 9.9% 
for PBS + light + siVEGF-A group when compared with PBS and 
PDT+siScrambled groups. The PDT+siVEGF-A group showed 
the lowest growth rate of −30.1% which is significantly different 
(P < 0.01) with PBS and PDT+siScrambled group showing simi-
lar enhancement effect in SCC4 xenograft models. The combined 
therapy showed significant tumor volume decrease to ~120% in 
SAS model as compared with untreated PBS group.
The excised tumor from the SCC4 and SAS xenograft models 
that were sacrificed on the 11th day were analyzed for VEGF-A 
mRNA and protein expression by qRT-PCR and western blotting, 
respectively. VEGF-A protein expression for groups treated with 
siVEGF-A-loaded LCP NPs significantly decreased (P < 0.01) 
based on the normalized band intensities against glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) when compared with 
PBS and PDT+siScrambled groups as shown in Figure 4a,b for 
SCC4 xenograft models and Figure 4e,f for SAS xenograft mod-
els. VEGF-A mRNA expression (Figure 4c,f) is in agreement with 
the protein expression results. The VEGF-A mRNA expression for 
groups treated with siVEGF-A–loaded LCP NPs showed signifi-
cant difference (P < 0.01) with PBS and PDT+siScrambled group.
It was expected that the VEGF-A expression would be higher 
for the PDT+siScrambled group but shows no significant increase 
Figure 2 Western blot analysis for in vitro VEGF-A and protein expres-
sions of sigma receptor. (a) Western blot analysis on the effect of PDT 
on VEGF-A expression after 24 hours and sigma receptor expression in 
SCC4 cell line. VEGF-A level was higher in PDT-treated cells that than in 
untreated control cells. (b) Western blot analysis on the effect of siRNA 
transfection on VEGF-A expression after 48 hours in SCC4 and SAS cell 
lines. VEGF-A level was downregulated in the siVEGF-A transfected cells.
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Figure 3 Tumor growth curves of HNSCC xenograft models. (a) Tumor growth rate of treated SCC4 xenograft. (b) Tumor growth rate of treated 
SAS xenograft. ▲ indicates i.v. injection of PBS and photosan with or without light. Δ indicates i.v. injection of targeted LCP with either siScrambled or 
siVEGF-A and PBS for control group. Data present as mean ± SD, n = 5. *P < 0.01 compared to PBS group; **P < 0.01 compared to PDT +siScrambled 





























































108 www.moleculartherapy.org vol. 24 no. 1 jan. 2016
© The American Society of Gene & Cell Therapy
VEGF-A siRNA Enhanced PDT for Head and Neck Cancer Therapy
when compared with the PBS group. The treatment days may have 
contributed to this effect that made the VEGF-A expression level 
returned to the same level as with untreated group. Reports show 
that VEGF protein levels increase 24 hours post-PDT.18
In vivo combined therapy inhibited tumor cell 
proliferation and activated tumor cell apoptosis
Tumors excised from mice after therapy were assayed for hematox-
ylin and eosin (H&E) staining (Figure 5), tumor cell proliferation 
(Ki-67), and tumor cell apoptosis (cleaved caspase-3, TUNEL) by 
immunohistochemistry (IHC) staining (Figure 6). H&E stains for 
the liver and kidney were also assayed and observed to have no cell 
damage (Figure 5). Hence, both liver and kidney were not affected by 
the treatment. As shown in the H&E stain for tumors (Figure 5a,c), 
after the full treatment in both SCC4 and SAS xenograft models, the 
control group (PBS) showed more mitotic figures than the treated 
groups (Figure 5b,d). The tumor cells undergoing metaphase where 
the chromosomes aligned at the center of the cell were visible as dark 
threads and postmetaphase (anaphase/telophase) was observed with 
two dark spots on a cell. Tumors that were treated showed a dras-
tic decrease in mitotic figures, but some chromosome condensa-
tions were observed due to the treatment. The decrease in mitotic 
figures coincided with the cell proliferation activity indicated by 
Ki-67 (Figure 6a,e). Ki-67 is a cellular marker that indicates whether 
the cell is active for cell proliferation. The quantified area for posi-
tive Ki-67 cells showed a dramatic decrease in the PDT+siVEGF-A 
group compared to PBS and PDT+siScrambled groups (P < 0.01) 
for both SCC4 (Figure 6b) and SAS (Figure 6f) indicating that the 
siVEGF-A-loaded LCP NPs enhanced the PDT effect and decreased 
the cell proliferation activity. PDT+siScrambled, PS+siVEGF-A, 
and PBS+Light+siVEGF-A groups also showed significant decrease 
(P  < 0.01) when compared to PBS group for both xenograft models 
Figure 4 Western blot analysis and VEGF-A mRNA level after treatment. HNSCC xenograft models were sacrificed on the 11th day, and tumors 
were excised for VEGF-A expression of the five treatment groups. Groups treated with targeted siVEGF-A show a decrease in VEGF-A mRNA and 
protein expression for both SCC4 and SAS. (a) Western blot for SCC4 xenograft models. (b) Quantified relative VEGF-A protein expression for SCC4 
xenograft models normalized against GAPDH band intensity. (c) Relative VEGF-A mRNA expression for SCC4 xenograft models. (d) Western blot 
for SAS xenograft models. (e) Quantified relative VEGF-A protein expression for SAS xenograft models normalized against GAPDH band intensity. 
(f) Relative VEGF-A mRNA expression for SCC4 xenograft models. Columns, mean (n = 3); bars, SD; *P < 0.01 compared with PBS group and 
PDT+siScrambled group. PBS, phosphate buffered saline; PDT, photodynamic therapy; PS, photosan; siScrambled, scrambled siRNA; siVEGF-A, 
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indicating that PDT alone and siVEGF-A-loaded LCP NPs contrib-
uted to the decrease of cell proliferation.
Caspase-3 plays an important role in apoptosis as its cleaved 
form indicates apoptosis while TUNEL assay detects DNA frag-
mentation that results from apoptotic signaling events. There was an 
increase in apoptotic cells for groups that received PDT, siVEGF-A, 
and the combination. There is a significant difference in the expres-
sion of cleaved caspase-3 and TUNEL-positive cells between all 
therapy groups when compared with PBS group (P < 0.01) as shown 
in Figure 6c,d for SCC4 xenograft models and Figure 6g,h for SAS 
xenograft models. The combined PDT+siVEGF-A for SCC4 xeno-
graft group showed dramatic cell killing effect that induced apo-
ptosis to 7% by cleaved caspase-3 (Figure 6c) and 10% based on 
TUNEL assay (Figure 6d). Similar to SCC4, SAS xenograft models 
also showed increased cell killing effect for PDT+siVEGF-A group 
with inducing 23 and 15% tumor cell apoptosis based on cleaved 
caspase-3 expression and TUNEL-positive cells, respectively 
(Figure 6g,h). The PDT+siVEGF-A, for both xenograft models, 
also showed significant difference between PDT+siScrambled indi-
cating that the siVEGF-A-loaded LCP NPs enhanced the tumor cell 
killing effect of the therapy when combined with PDT.
In vivo combined therapy inhibited tumor 
angiogenesis
We also evaluated the tumor microvessel formation (CD31), 
matured blood vessel (α-SMA), and tumorangiogenic marker 
Figure 5 H&E staining of liver, kidney, and tumor tissue sections of HNSCC xenograft models. SCC4 xenograft models were sacrificed on the 
11th day. (a) Tissue morphology of liver, kidney, and tumor for SCC4. (b) Mitotic figure count for SCC4 tumor tissue sections. (c) Tissue morphol-
ogy of liver, kidney, and tumor for SAS. (d) Mitotic figure count for SAS tumor tissue sections. Columns, mean (n = 5 per group); bars, SD; *P < 0.01 
compared to PBS group. Bar = 100 µm. PBS, phosphate buffered saline; PDT, photodynamic therapy; PS, photosan; siScrambled, scrambled siRNA; 
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(VEGF-A) by IHC staining in both xenograft models (Figure 7a,e). 
The quantified microvessel density (Figure 7b,f) showed a dra-
matic decrease in groups treated with siVEGF-A loaded in LCP 
NPs for both xenograft models when compared with PBS group 
(P < 0.01). These groups also showed significant difference with 
PDT+siScrambled group (P < 0.01) indicating that the siVEGF-
A–loaded LCP NPs had an effect on the decrease on the formation 
of tumor microvasculature.
The α-SMA plays a role in blood vessel maturity which means 
it is associated with tumor growth, and the immunostaining also 
revealed similar trend with CD31 (Figure 7a,e). Based on the quan-
tified values, there a significant decrease in mature blood vessel for-
mation for both xenograft models treated with siVEGF-A–loaded 
LCP NPs when compared with PBS and PDT+siScrambled groups 
as shown in Figure 7c,g. The decrease of α-SMA may also be related 
to the decrease of tumor-associated fibroblast formation. This effect 
may come from the silencing of VEGF-A where a decrease expres-
sion is expected thus formation of blood vessel is lessened.
The expression of the main angiogenic marker, VEGF-A, 
was also evaluated and quantified (Figure 7). It was observed 
that the tumor VEGF-A expression is high with PBS and 
PDT+siScrambled groups indicating that it is highly expressed on 
malignant cells. SAS tumor showed higher VEGF-A protein levels 
than SCC4 which may contribute to the fact that SAS tumor cells 
have higher cell proliferation and mitotic figures. Groups treated 
with siVEGF-A-loaded LCP NPs showed less tumor VEGF-A 
expression (Figure 7d,h) which indicates that it is silenced. The 
silencing effect of VEGF-A expression may contribute to the 
decrease of microvessel and mature blood vessel formations lead-
ing to lesser mitotic figures and induction of tumor cell apoptosis 
especially with the combined therapy.
In vivo toxicity assay
The siVEGF-A–loaded LCP NPs were tested for toxicity and 
if it could affect both liver and kidney functions (Table 1). The 
C57BL/6 mice were separated into three groups that were given 
daily i.v. injections of PBS, siScrambled-loaded LCP NPs, and 
siVEGF-A–loaded LCP NPs for 3 days and sacrificed on the fourth 
day. The blood was collected by cardiac puncture. The aspartate 
aminotransferase and alanine aminotransferase for liver function 
did not show any significant difference (P > 0.05) for siScrambled 
and siVEGF-A groups compared to PBS group showing no liver 
function damage observed. Similar with the kidney function, the 
blood urea nitrogen has no significant difference (P > 0.05) as well 
as with phosphorus and calcium levels. This indicates that even 
the core of the LCP NPs is made of CaP it did not affect the kidney 
function. Assayed concentrations of Toll-like receptor 3 (TLR3) of 
three groups (PBS, siScrambled, and siVEGF-A groups) showed 
no significant activation of TLR3 concentration of mouse serumn 
in triplicates (P > 0.05) using TLR3 ELISA kit (MyBioSource, San 
Diego, CA) (Table 1). This in vivo toxicity assay indicates that the 
LCP NPs are biologically safe in animal study.
DISCUSSION
In this study, we combined PDT with a novel lipid-based nanopar-
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human HNSCC. The CaP core of these nanoparticles is pH sensi-
tive that can be easily dissolved in the endosome and release the 
entrapped siRNA into the cytoplasm where the RNA-induced 
silencing complex resides.19 These LCP NPs has an asymmetric 
bilayer of anionic (dioleoylphosphatidic acid) and cationic (1,2-dio-
leoyl-3-trimethylammonium-propane chloride salt:cholesterol = 
1:1) lipids that are PEGylated to prolong in vivo circulation time 
and improve cellular uptake.20 The outer leaflet is coated with AA 
that targets sigma receptor which is overexpressed in a number of 
human cancer cells which includes HNSCC cells.16 TEM photomi-
crographs revealed that the LCP NPs are uniformly dispersed and 
stabilized due to PEGylation (Figure 1b) with particle size ranging 
from 35 to 40 nm and a 46.2 mV showing colloidal stability (Figure 
1d). The size obtained of the nanoparticles is appropriate to access 
tumor cells.21 The biodegradable CaP core and the asymmetric 
lipid bilayer structure of the nanoparticle is biologically safe since 
no liver and kidney damage were observed (Table 1).
It is known that PDT mediates the increase of HIF and its target 
genes. Mitra et al. presented that PDT mediates hypoxia in an oxy-
gen-independent manner and activates HIF-1α and its target genes.6 
It was previously shown that VEGF-A is expressed in oral squamous 
cell carcinoma and relates it with tumor angiogenesis.12 We found 
that HNSCC cells express VEGF-A protein and it was upregulated 24 
hours after PDT treatment in SCC4 cell line previously (Figure 2a). 
We proved that PDT does induce more VEGF-A protein expression 
in HNSCC and such angiogenesis protein facilitates tumor growth. 
Ferrario et al. found that PDT-mediated hypoxia and oxidative stress 
induced the expression of HIF-1α and VEGF levels in BA mouse 
mammary carcinoma.10 In addition, PDT induced the expression 
of HIF-1α and VEGF in glioma cells proving that PDT can medi-
ate hypoxic conditions to tumor cells.22 One strategy to mitigate 
the expression of VEGF-A is to introduce siRNA that is specific for 
VEGF-A. A study conducted by Tong et al.11 showed that HNSCC 
cells transfected with 30 and 50 nmol/l VEGF siRNA inhibited the 
endogenous VEGF production proving that VEGF expression can 
be inhibited at cellular level using siRNA specific to VEGF-A.
VEGF-A was upregulated 24 hours after PDT treatment and 
the novel self-designed VEGF-A siRNA silence VEGF-A protein 
expression effectively. Combined in vivo therapy was designed 
to perform PDT first followed by i.v. injection of siVEGF-A-
loaded LCP NPs. The effect of PDT was observed with the 
PDT+siScrambled group. It shows that PDT affects the decrease 
of tumor cell proliferation and induces cell apoptosis. However, 
the VEGF-A mRNA and protein expression levels were not 
affected by PDT leading to increased CD31 and α-SMA expres-
sion. The antiangiogenic effect of the siVEGF-A–loaded LCP NPs 
Figure 6 HNSCC tumor cell proliferation and apoptosis. HNSCC xenograft models of (a–d) SCC4 and (e–h) SAS were sacrificed on the 11th day 
after treatment. IHC staining against Ki-67 for tumor cell proliferation, cleaved caspase-3, and TUNEL assay for tumor cell apoptosis for (a,e) tumor 
tissue sections and quantitative analysis for (b,f) Ki-67, (c,g) cleaved caspase-3, and (d,h) TUNEL assay. Columns, mean (10 images); bars, SD; 
*P < 0.01 compared to PBS group; **P < 0.01 compared to PDT+siScrambled group. Bar = 100 µm. PBS, phosphate buffered saline; PDT, photody-
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was observed in groups with incomplete PDT (PS+siVEGF-A and 
PBS+Light+siVEGF-A) proving that the siVEGF-A was success-
fully delivered to the tumor cells leading to the decreased mRNA 
and protein expression of VEGF-A. There was also a decrease in 
tumor cell proliferation and increased cell apoptosis observed 
showing that the gene therapy is effective. The combined therapy 
of PDT and siVEGF-A–loaded LCP NPs showed the best tumor 
growth inhibition where a drastic decrease in tumor volume was 
observed (Figure 3). VEGF-A mRNA and protein expression 
for the combined therapy showed significant decrease that is 
also reflected in VEGF-A IHC staining (Figure 7). The decrease 
in VEGF-A expression coincides with the drastic decrease in 
microvessel density and α-SMA–positive fibroblasts may be 
directed to the decrease of tumor cell proliferation and induced 
cell apoptosis (Figure 6). Similar antiangiogenic effect was 
observed with PDT that has been combined with other antiangio-
genic molecules such as anti-VEGF monoclonal antibody (beva-
cizumab) in epithelial human bladder carcinoma cell line.7,13 They 
showed the tumor inhibition effect of combined PDT and beva-
cizumab leading to the decrease of VEGF expression13 even when 
combined with an anti-EGFR monoclonal antibody (cetuximab).7
In summary, PDT combined with siVEGF-A loaded in LCP 
NPs has the potential to enhance the therapeutic efficacy of PDT 
in HNSCC by silencing the VEGF-A angiogenic marker.
MATERIALS AND METHODS
Materials. Photosan was acquired from SeeLab (Wesselburenerkoog, 
Germany). Self-designed VEGF-A siRNA (siVEGF-A) with sense strand 
5′- UCC GCA GAC GUG UAA AUG UdTdT-3′ was designed using the pro-
vided webserver of Whitehead Institute webserver23 and scrambled siRNA 
(siScrambled) with sense strand 5′- AUG UAU UGG CCU GUA UUA 
GdTdT-3′ were all purchased from Dharmacon. (Thermoscientific, Lafayette, 
CO). Lipofectamine RNAiMAX was purchased from Invitrogen (Carlsbad, 
CA). 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly
ethyleneglycol-2000)] ammonium salt (DSPE-PEG2000), dioleoylphospha-
tidic acid, and 1,2-dioleoyl-3-trimethylammonium-propane chloride salt 
were purchased from Avanti Polar Lipids (Alabaster, AL). DSPE-PEG-AA 
was synthesized in our lab as described previously.24 Other chemicals were 
obtained from Sigma-Aldrich (St Louis, MO) without further purification.
Cell culture. Human squamous cell carcinoma cells, SCC4, were purchased 
from Bioresource Collection and Research Center (BCRC, Hsinchu, 
Taiwan, ROC), and SAS was a gift from Prof Liu, Yang Ming University. 
Cells were cultured in Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F-12) medium (Invitrogen, Grand, Island, NY) 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen) and incu-
bated at 37 °C with 5% CO2. When cell reached 70% confluence, the cells 
were detached from adhesion with 0.05% trypsin-EDTA (Invitrogen) 
before subculture in DMEM/F-12 medium.
In vitro PDT. SCC4 cells (3 × 105 cells/well) were seeded on each well of a 
24-well plate and incubated overnight. After it reached 70% confluence, the 
cells were incubated with 0.5 µg/ml photosan in DMEM/F-12 medium in the 
absence of FBS for 2 hours and then were irradiated with light energy dose of 
10 J/cm2 for 159 seconds. Finally, the cells were incubated with DMEM/F-12 
medium with 10% FBS for 48 hours before cell lysate collection.
In vitro siRNA transfection. SCC4 or SAS cells (3 × 105 cells/well) 
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Transfection was performed with different 25 nmol/l concentration of 
siRNA in Opti-MEM Reduced medium (Invitrogen) using Lipofectamine 
RNAiMAX (Invitrogen) according to manufacturer’s instructions. Cells 
were then incubated at 37 °C for 4 hours in Opti-MEM Reduced medium 
and changed with growth medium (with 10% FBS) for 48 hours. Cell lysate 
were collected after 48 hours.
Formulation of LCP NPs. LCP NPs were prepared as described previously 
with slight modifications.20 The target moiety of LCP NPs surface is AA to 
recognize sigma receptors on the surface of SCC4 or SAS. Briefly, 300 µl 
of 2.5 mol/l CaCl2 with 12 µg of siRNA was dispersed in a 20 ml oil phase 
(cyclohexane/Igepal CO-250 (71/29, v/v)) to form a well-dispersed water-
in-oil microemulsion. The phosphate microemulsion was prepared by dis-
persing 300 µl of 12.5 mmol/l Na2HPO4 in a separate 20 ml oil phase. One 
hundred microliters of 20 mmol/l dioleoylphosphatidic acid in chloroform 
was added to the phosphate solution. After mixing the above two micro-
emulsions for 20 minutes, 40 ml of ethanol was added to the combined 
solution, and the mixture was centrifuged. After three cycles of ethanol 
wash, the CaP core pellets were dissolved in chloroform. To prepare the 
final LCP NPs, 500 µl of CaP core was mixed with 75 µl of 10 mmol/l 
1,2-dioleoyl-3-trimethylammonium-propane chloride salt, 10 mmol/l 
cholesterol, 3 mmol/l DSPE-PEG-2000, and 3 mmol/l DSPE-PEG-AA. 
After evaporating the chloroform, the residual lipid was hydrated in 200 µl 
of 5% glucose to form LCP NPs.
Characterization of LCP NPs. Particle size and zeta potential of the LCP 
NPs were measured using Malvern Zetasizer Nano series (Westborough, 
MA). TEM images of LCP were acquired using Bio-TEM Hitachi HT7700 
(Hitachi, Japan).
Establishment of HNSCC xenograft models for therapy. SCC4 or SAS 
cells (6 × 105 cells) in 160 µl medium were mixed with 250 µl Matrigel 
(Corning, Bedford, MA) and subcutaneously injected using a 28-gauge 
needle at the lower right dorsal flank of 6–8-week-old male BALB/
Table 1 Serum levels for blood markers
AST (U/l) ALT (U/l) BUN (mg/dl) Phosphorus (mg/dl) Calcium (mg/dl) TLR3 (ng/ml)
PBS 58.3 ± 6.8 23.1 ± 3.3 30.6 ± 4.8 10.7 ± 1.3 11.1 ± 0.5 0.092 ± 0.030
siScrambled*Â Â 78.3 ± 32.7 22.1 ± 5.8 30.3 ± 1.2 10.8 ± 0.9 11.1 ± 0.2 0.081 ± 0.014
siVEGF-A* 77.9 ± 26.5 32.4 ± 11.6 29.3 ± 0.8 10.2 ± 0.9 11.2 ± 0.5 0.086 ± 0.010
Data are given in mean ± SD, n = 3.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; PBS, phosphate buffered saline; TLR3, Toll like receptor 3.
*P > 0.05 compared to PBS.
Figure 7 HNSCC tumor angiogenesis. HNSCC xenograft models of (a–d) SCC4 and (e–h) SAS were sacrificed on the 11th day after treatment. 
(a,e) IHC staining against CD31, α-SMA, and VEGF-A and quantitative analysis for (b,f) CD31, (c,g) α-SMA, and (d,h) VEGF-A. Columns, mean (10 
images); bars, SD; *P < 0.01 compared to PBS group; **P < 0.01 compared to PDT+siScrambled group. Bar = 100 µm. PBS, phosphate buffered saline; 
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cAnN.Cg-Foxn1nu (National Laboratory Animal Center, Taipei, Taiwan) 
nude mouse. SCC4 or SAS xenograft model were randomly separated 
into five groups (n = 5 per group): (i) PBS; (ii) PDT+siScrambled; (iii) 
PS+siVEGF-A; (iv) PBS+Light+siVEGF-A; and (v) PDT+siVEGF-A. 
Treatment protocol is shown in Supplementary Table S1. The five treat-
ments were given i.v. by tail vein injection. The dose of LCP NPs loaded 
with either siScrambled or siVEGF-A was 0.36 mg/kg. Photosan was i.v. 
injected with a dosage of 2 mg/kg prepared by dissolving 0.05 mg photo-
san in 200 µl PBS for every 25 g weight of mouse. After 55 minutes post i.v. 
injection, the light was set to a power density of 320 mW/cm2, and energy 
dosage of 100 J/cm2 for 11 minutes with 2 cm distance from the surface 
of the tumor. Treatment procedure was carried out when tumors reached 
350 mm3 ± 10% (315–385 mm3). Tumor volume was calculated using the 
following formula: V  =  0.5 × (L × W × H), where V stands for tumor 
volume, L stands for the length, W stands for the width perpendicular 
with the length, and H stands for the height of the tumor. Tumor size were 
measured daily by digital caliper, and the mice were sacrificed on the 11th 
day. Excised SCC4 and SAS tumors and organs were dissected and fixed in 
10% formalin for further experiments. These studies were approved and 
carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of the Institutional Animal Care and Use Committee 
of Chung Yuan Christian University, Chungli, Taoyuan, Taiwan, ROC.
Western blot analysis. Cells and excised tumors were homogenized and 
lysed in the lysis buffer (PRO-PREP protein extraction solution; Intron 
Biotechnology, Seoul, Korea). Samples with equal amount of protein 
using BCA protein assay kit (Pierce, Thermo Fisher Scientific, Rockford, 
IL) were denatured in sample buffer at 100 °C for 5 minutes. Prepared 
samples were resolved on 5%/12% Bis–Tris acrylamide gels (stacking/
separating gel) along with protein markers. sodium dodecyl sulfate–
polyacrylamide gel electrophoresis was carried out at constant voltage 
(150 V) at room temperature. Proteins were electrophoretically trans-
ferred to an Immobilon-P PVDF membrane (Millipore, Billerica, MA) 
at 4 °C at constant 300 mA for 2 hours. Following the transfer, the PVDF 
membrane was blocked with BlockPRO blocking buffer (Visual Protein 
Biotechnology, Taipei, Taiwan), incubated with rabbit primary antibod-
ies against VEGF (VEGF-A GTX102643; GeneTex, Taipei, Taiwan, ROC; 
1:1,500 dilution) and sigma receptor (SIGMAR1 GTX115389; GeneTex; 
1:1,000 dilution), respectively, followed by peroxidase-conjugated goat 
antirabbit IgG (GTX213110 GeneTex; 1:10,000 dilution), and then devel-
oped in enhanced chemiluminescence substrate (PerkinElmer, Boston, 
MA). GAPDH (GTX100118; GeneTex; 1:1,000 dilution) was used as 
an internal control. Intensities of hybridized protein bands on western 
blots were quantified (n = 3) using Image J software (National Institutes 
of Health), and blots were scanned using Fusion Solo imaging system 
(VilberLourmat, Cedex, France).
Quantitative real-time PCR. A total of 0.05 g tumor tissues from the 
treatment groups of SCC4 and SAS were homogenized to extract total 
tissue RNA using RNAzol RT (Molecular Research Center, Cincinnati, 
OH). Then, cDNAs were synthesized with RevertAid First Strand cDNA 
Synthesis Kit (Fermentas, Thermo Scientific, Waltham, MA). Quantitative 
real-time PCR was performed with FastStart Universal Probe Master 
(Roche Applied Science, Mannheim, Germany). Reactions were run 
with a standard cycling program: 95 °C for 10 minutes, 40 cycles of 95 
°C for 15 seconds and 60 °C for 1 minute on an AB7300 real-time PCR 
system (Applied Biosystems, Foster City, CA). The primer sequences 
for human VEGF-A were: forward, 5′-TGCCCGCTGCTGTCTAAT-3′; 
reverse, 5′-TCTCCGCTCTGAGCAAGG-3′. The primer sequences for 
human GAPDH were: forward, 5′-AGCCACATCGCTCAGACAC-3′; 
reverse, 5′-AGCCACATCGCTCAGACAC-3′. The primer pairs were 
synthesized by Roche (Roche Applied Science, Mannheim, Germany). 
Results were calculated based on the relative number of threshold cycles 
normalizing the calculated VEGF-A concentration values with GAPDH 
concentration values.
H&E staining and IHC. Tissues embedded in paraffin and cut into sections 
followed by standard H&E staining protocol. Paraffin-embedded sections 
of SCC4 and SAS tumor tissues were deparaffinized and hydrated fol-
lowed by antigen retrieval for IHC staining. Endogeneous peroxidase was 
inactivated by hydrogen peroxide for 10 minutes. Tumor tissue sections 
were treated with rabbit polyclonal anti-CD31 (1:100, ab28364; Abcam, 
Cambridge, MA), rabbit monoclonal anti-Ki-67 (1:200, ab16667; Abcam), 
rabbit polyclonal anti-VEGF-A (1:300, ab46154; Abcam), and monoclo-
nal mouse antihuman RTU α-SMA (IR611; Dako Agilent Technologies, 
Carpinteria, CA) by following manufacturer’s instructions. Tumor tissue 
sections were incubated with horseradish-peroxidase-conjugated antirab-
bit antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min-
utes. Visualization of slides was achieved with a DAB detection kit (Pierce, 
Rockland, IL) and mouse detection kit (Golden Bridge International, 
Bothell, WA) for α-SMA. All specimens were examined using an Olympus 
BX53F light microscope (Olympus, Tokyo, Japan). Mitotic figures were 
quantified for SCC4 and SAS tumor tissue sections (five images per group) 
by counting mitotic cells manually at ×40 magnification using an Olympus 
BX53F light microscope (Olympus, Tokyo, Japan). IHC stain density was 
quantified at ×40 magnification (10 images per group) using Image J soft-
ware (National Institutes of Health).
TUNEL assay. Paraffin-embedded SCC4 and SAS tumor tissue sections 
were deparaffinized, rehydrated, and pretreated for protease. TUNEL assay 
was performed using In situ Cell Death Detection Kit, POD (catalogue 
no. 11 684 817 910; Roche, Mannheim, Germany), by following manu-
facturer’s instructions. All specimens were examined using an Olympus 
BX53F light microscope (Olympus, Tokyo, Japan). TUNEL-positive cells 
were quantified at ×40 magnification (10 images per group) using Image J 
software (National Institutes of Health, http://imagej.nih.gov/ij/).
In vivo toxicity assay. The 6–8-week-old C57BL/6JNarl mice (n = 3 per 
group) were tail vein injected with PBS, siScrambled, and siVEGF-A 
loaded in LCP NPs for three consecutive days and repeated the three injec-
tions after 2 days. Mice were anesthetized and sacrificed at eighth day using 
cardiac puncture after last injection. The collected blood was slowly trans-
ferred in a 1.5 ml Eppendorf tube and was allowed to clot at room tem-
perature for 20 minutes before centrifugation at 4,000 rpm for 10 minutes 
at 4 °C using a refrigerated benchtop centrifuge (HERMLE Z233 MK-2; 
HERMLE, Wehingen, Germany). The collected serum was analyzed for 
levels of secreted liver biomarkers (aspartate aminotransferase and alanine 
aminotransferase) and kidney biomarkers (creatinine, blood urea nitro-
gen, calcium, and phosphorus). TLR3 concentrations were investigated 
to evaluate there is no activation of innate immune response using TLR3 
ELISA kit (MyBioSource, San Diego, CA).
Statistical analysis. Data presented as mean values ± SD. Statistical sig-
nificance was determined using one-way ANOVA using SigmaPlot (Systat 
Software, San Jose, CA). P < 0.01 was considered significant.
SUPPLEMENTARY MATERIAL
Table S1. SCC4 and SAS xenograft model treatment group.
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